Trial · NCT00950989
Results by group73
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 73
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | Placebo | 12.7 | percentage of participants | ||
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | Brodalumab 70 mg | 15.9 | percentage of participants | ||
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | Brodalumab 140 mg | 15.9 | percentage of participants | ||
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | Brodalumab 210 mg | 9.5 | percentage of participants | ||
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Placebo | 42.9 | percentage of partcipants | ||
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Brodalumab 70 mg | 39.7 | percentage of partcipants | ||
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Brodalumab 140 mg | 36.5 | percentage of partcipants | ||
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Brodalumab 210 mg | 46.0 | percentage of partcipants | ||
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | Placebo | 3.2 | percentage of participants | ||
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | Brodalumab 70 mg | 3.2 | percentage of participants | ||
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | Brodalumab 140 mg | 3.2 | percentage of participants | ||
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | Brodalumab 210 mg | 0.0 | percentage of participants | ||
| Disease Activity Score 28 (DAS28) at Week 12 | Placebo | 5.0 | Standard Error 0.2 | score on a scale | |
| Disease Activity Score 28 (DAS28) at Week 12 | Brodalumab 70 mg | 4.9 | Standard Error 0.2 | score on a scale | |
| Disease Activity Score 28 (DAS28) at Week 12 | Brodalumab 140 mg | 5.1 | Standard Error 0.2 | score on a scale | |
| Disease Activity Score 28 (DAS28) at Week 12 | Brodalumab 210 mg | 5.1 | Standard Error 0.2 | score on a scale | |
| Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Placebo | AEs | 32 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Brodalumab 70 mg | AEs | 32 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Brodalumab 140 mg | AEs | 40 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Brodalumab 210 mg | AEs | 32 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00950989/results